{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:32:15Z","timestamp":1788982335760,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010514","name":"Seattle Children\u2019s Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010514","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jcf.2021.05.013","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T23:40:19Z","timestamp":1623800419000},"page":"1010-1017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1913-9171","authenticated-orcid":false,"given":"Diana","family":"Bilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-1486","authenticated-orcid":false,"given":"Isabelle","family":"Fajac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tacjana","family":"Pressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Paul","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4601-5158","authenticated-orcid":false,"given":"Dorota","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Predrag","family":"Minic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-7248","authenticated-orcid":false,"given":"Marco","family":"Cipolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivanka","family":"Galeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra L.","family":"Quittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanna","family":"Jumadilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Ciesielska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-7277","authenticated-orcid":false,"given":"Michael W.","family":"Konstan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2021.05.013_bib0001","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2021.05.013_bib0002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.05.013_bib0003","unstructured":"Cystic Fibrosis Foundation. Cystic fibrosis foundation patient registry 2018 patient registry annual data report. https:\/\/www.cff.org\/Research\/Researcher-Resources\/Patient-Registry\/2018-Patient-Registry-Annual-Data-Report.pdf. Accessed April 20, 2021."},{"key":"10.1016\/j.jcf.2021.05.013_bib0004","unstructured":"European Cystic Fibrosis Society. Cystic fibrosis in Europe facts and figures. 2017. At-a-glance report. https:\/\/www.ecfs.eu\/sites\/default\/files\/general-content-files\/working-groups\/ecfs-patient-registry\/At-a-Glance_2017_ECFSPR.pdf. Accessed April 20, 2021."},{"key":"10.1016\/j.jcf.2021.05.013_bib0005","unstructured":"Cystic Fibrosis Worldwide. What is cystic fibrosis? https:\/\/www.cfww.org\/what-is-cystic-fibrosis. Accessed June 7, 2021."},{"key":"10.1016\/j.jcf.2021.05.013_bib0006","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fmed.2017.00176","article-title":"Acute exacerbation in interstitial lung disease","volume":"4","author":"Leuschner","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.jcf.2021.05.013_bib0007","doi-asserted-by":"crossref","first-page":"e00019","DOI":"10.1128\/CMR.00019-18","article-title":"Epidemiology, biology, and impact of clonal Pseudomonas aeruginosa infections in cystic fibrosis","volume":"31","author":"Parkins","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jcf.2021.05.013_bib0008","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12890-016-0333-y","article-title":"Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time","volume":"16","author":"Crull","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jcf.2021.05.013_bib0009","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1183\/09031936.05.00050304","article-title":"Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre","volume":"25","author":"Van Daele","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2021.05.013_bib0010","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jcf.2019.08.006","article-title":"Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis-data from the European cystic fibrosis society patient registry","volume":"19","author":"Hatziagorou","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.05.013_bib0011","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1128\/CMR.00068-09","article-title":"The changing microbial epidemiology in cystic fibrosis","volume":"23","author":"Lipuma","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jcf.2021.05.013_bib0012","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1378\/chest.09-0132","article-title":"Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005","volume":"136","author":"Razvi","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2021.05.013_bib0013","unstructured":"Zolin, A., Orenti, A., Naehrlich, L., van Rens, J., Fox, A., Krasnyk, M., et\u00a0al. on behalf of the ECFSPR. ECFS Patient Registry annual data report 2017. https:\/\/www.ecfs.eu\/sites\/default\/files\/general-content-images\/working-groups\/ecfs-patient-registry\/ECFSPR_Report2017_v1.3.pdf. Accessed April 20, 2021."},{"key":"10.1016\/j.jcf.2021.05.013_bib0014","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","article-title":"Consensus Study G. Treatment of lung infection in patients with cystic fibrosis: current and future strategies","volume":"11","author":"Doring","year":"2012","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.05.013_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/pathogens6010010","article-title":"Interactions between neutrophils and Pseudomonas aeruginosa in cystic fibrosis","volume":"6","author":"Rada","year":"2017","journal-title":"Pathogens"},{"key":"10.1016\/j.jcf.2021.05.013_bib0016","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jcf.2014.03.010","article-title":"European Cystic Fibrosis Society standards of care: best practice guidelines","volume":"13","author":"Smyth","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.05.013_bib0017","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2021.05.013_bib0018","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.05.013_bib0019","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jac\/dkn059","article-title":"Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections","volume":"61","author":"Meers","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcf.2021.05.013_bib0020","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2021.05.013_bib0021","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2019.08.001","article-title":"Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis","volume":"19","author":"Bilton","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.05.013_bib0022","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jcf.2017.10.015","article-title":"Development and electronic validation of the revised Cystic Fibrosis Questionnaire (CFQ-R Teen\/Adult): new tool for monitoring psychosocial health in CF","volume":"17","author":"Sole","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.05.013_bib0023","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1183\/09031936.00166412","article-title":"Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry","volume":"43","author":"Kerem","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2021.05.013_bib0024","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1513\/AnnalsATS.201703-254ED","article-title":"Preserving lung function: the holy grail in managing cystic fibrosis","volume":"14","author":"Sly","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2021.05.013_bib0025","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcf.2016.07.012","article-title":"Reduced survival in adult cystic fibrosis despite attenuated lung function decline","volume":"16","author":"Keating","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.05.013_bib0026","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jcf.2015.10.014","article-title":"A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: a single-center study","volume":"15","author":"Maliniak","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2021.05.013_bib0027","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.05.013_bib0028","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ppul.20625","article-title":"Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis","volume":"42","author":"Gibson","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2021.05.013_bib0029","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ppul.21301","article-title":"An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis","volume":"45","author":"Oermann","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2021.05.013_bib0030","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial","volume":"65","author":"Ratjen","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2021.05.013_bib0031","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Freedom Study G. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2021.05.013_bib0032","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1378\/chest.08-1421","article-title":"Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis","volume":"135","author":"Retsch-Bogart","year":"2009","journal-title":"Chest"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199321001648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199321001648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:44:41Z","timestamp":1761601481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199321001648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1569199321001648"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2021.05.013","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2021.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}